[
    {
        "page_number": 1,
        "text": "DILUTION GUIDELINE  \nFOR INJECTABLE DRUGS\nPHARMACEUTICAL SERVICES PROGRAMME\nMINISTRY OF HEALTH, MALAYSIAMOH /S/FAR/11.20(GU) -e"
    },
    {
        "page_number": 3,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nMOH/S/FAR/11.20(GU) -e\nNo. Rujukan: A-GU-84\nNo. Keluaran: 1\nDecember 2020\n© All Rights Reserved\nThis isapublication ofthePharmaceutical Services Programme, Ministry ofHealth Malaysia.\nPermission ishereby granted toreproduce information contained herein provided that such\nreproduction begiven due acknowledgement and shall notmodify thetext.Enquiries aretobe\ndirected totheaddress below .\nPharmaceutical Services Programme\nMinistry ofHealth Malaysia\nLot 36, Jalan Universiti ,\n46200 Petaling Jaya, Selangor, Malaysia  \nTel:603–7841 3200 Fax: 603–7968 2222\nWebsite: www.pharmacy.gov.my"
    },
    {
        "page_number": 4,
        "text": "DILUTION GUIDELINE\nFOR INJECTABLE DRUGS\n(Part I –Antimicrobial)"
    },
    {
        "page_number": 5,
        "text": "1DILUTION GU ID E LIN E  FOR IN JE C T ABLE DRUGS\nDILUTION GUIDELINE FORINJECTABLEDRUGS\nPublication date December 2020\nSummary Dilution Guideline forInjectable Drugs serves asageneral reference for\nhealthcare professionals onthe preparation ofinjectable drugs before\nadministering tothepatient .\nThe information provided inthis guideline ismainly extracted from the\npackage insert forrelevant brand ofinjectable drugs used and valid atthe\ntime ofpublication .Nevertheless, users arestrongly advised torefer tothe\ndilution instruction asstated intheproduct package insert currently used\nattherespective facilities and update regularly .\nAuthor Medication Safety Section\nPharmacy Practice and Development Division  \nPharmaceutical Services Programme\nMinistry of Health Malaysia\nApplies to Allgovernment and private healthcare facilities\nAudience Healthcare professionals\nReview Date December 2025"
    },
    {
        "page_number": 6,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nTABLE OFCONTENT\n2CONTENTPAGE  \nNUMBER\nDisclaimer  4\nPreface 4\nForeword 5\nAcknowledgement 6\nReviewers 6\nAccreditors 7\nEditorial Board 8\nAbbreviations &Acronyms 9\nList ofDrugs\n■Acyclovir Injection 10\n■Amikacin Injection 11\n■Amoxicillin & Clavulanate Injection 12 \n■Amphotericin BInjection 13\n■Ampicillin Injection 14\n■Ampicillin & Sulbactam Injection 15\n■Anidulafungin Injection 16\n■Artesunate Injection 17\n■Azithromycin Injection 18\n■Benzathine Penicillin Injection 19\n■Benzylpenicillin Injection 20\n■Caspofungin Acetate Injection 21\n■Cefazolin Injection 23\n■Cefepime Injection 24\n■Cefoperazone Injection 25\n■Cefoperazone & Sulbactam Injection 26\n■Cefotaxime  Injection 27\n■Ceftazidime Injection 28\n■Ceftriaxone Injection 29\n■Cefuroxime Injection 31\n■Clindamycin Injection 32\n■Cloxacillin Injection 33\n■Ertapenem Injection 34"
    },
    {
        "page_number": 7,
        "text": "3DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCONTENTPAGE  \nNUMBER\n■Erythromycin Lactobionate Injection 35\n■Ganciclovir Injection 36\n■Gentamicin Injection 37\n■Imipenem & Cilastatin Injection 38\n■Meropenem Injection 39\n■Micafungin Injection 40\n■Netilmicin Injection 41\n■Pentamidine Isethionate Injection 42\n■Piperacillin & Tazobactam Injection 43\n■Sulphamethoxazole –Trimethoprim Injection 44\n■Vancomycin Injection 45\n■Voriconazole Injection 46\n■Zidovudine Injection 48\nAppendices 49\nReferences 55"
    },
    {
        "page_number": 8,
        "text": "4DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nDISCLAIMER\nThis guideline serves asageneral reference forthe healthcare professionals inthe Ministry of\nHealth onhow toprepare dilution ofcertain injectable drugs before administering tothepatient .\nThe information provided inthis guideline mainly extracted from the package insert forthe\nbrand ofinjectable drugs used and valid atthe time ofpublication .Nevertheless, users are\nstrongly advised torefer tothe dilution instruction asstated inthe product package insert\ncurrently used attherespective facilities and update regularly .\nThe medicines included inthis guideline areselected from the Ministry ofHealth Medicines\nFormulary (MOHMF) .\nThe users ofthis guideline must have thenecessary knowledge and competen cyinorder to\ninterpret the information provided .Innoevent shall thePharmaceutical Services Programme\nbeliable forany direct, indirect, incidental, special orconsequential event resulting from the\nuse ofortheinability touse thisguideline .The committee reserves theright toamend, update\norremove thecontent ofthis guideline when necessary .\nPREFACE\nThe Malaysian National Patient Safety Council Technical Committee onMedication Safety had\nput inm uch effort through thevarious stakeholders topromote medication safety culture inboth\nthepublic and private healthcare sector .The primary goal ofmedication safety istoensure long\nterm and continuous quality improvements inhealthcare .One way ofachieving itisby\nimproving and strengthening medication safe practice .Hence, Pharmaceutical Services\nProgramme, Ministry ofHealth Malaysia has taken the initiative and prepared the Dilution\nGuideline forInjectable Drugs .\nThe purpose ofthis guideline istoprovide information and facilitate thehealthcare professionals\natalllevel sinthe preparation ofinjectable drugs that are listed inthe Ministry ofHealth\n(MOH) drug formulary which require sdilution .This guideline will also serve asapreventive\nmeasure toreduce medication errors related toincorrect dilution and administration of\ninjectable drugs ."
    },
    {
        "page_number": 9,
        "text": "5DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nMedication safety has received much attention\nafter theInstitute ofMedicine had published “To\nErrIsHuman :Building aSafer HealthSystem”\nreport which was inline with the third World\nHealth Organization (WHO) Global Patient\nSafety Challenge .Errors can never beentirely\neliminated, buttheir numbers andseverity canbe\nreduced .Theoccurrence ofmedication errors can\ncompromise patients’ confidence inhealthcare\nsystem byexposing them totheriskofadverse\ndrug reactions and increase dhealthcare cost.\nMoreover, medication errors arepreventable .\nThe Malaysian Patient Safety Council, Ministry of\nHealth (MOH) had put inmuch effort through\nthevarious stakeholders topromote medication\nsafety culture inboth the public and private\nhealthcare sectors .Pharmaceutical Services\nProgramme, MOH hasbeen given amandate to\nlead theTechnical Working Group ofMedication\nSafety atthenational level.Thecommittee, which\ncomprises various stakeholders, willidentify any\nissues related tomedication safety and plan for\nongoing improvements inthequality and safety\nofthe medication management system and\npractices .\nWith the aim ofreducing the risksrelated to\ninjectable drugs, initiatives have been taken to\nestablish Dilution Guidelines for Injectable\nDrugs topromote safe medication use.Moreover,\nerrors inintravenously administered medications\nmay have serious consequences and incident\ncan happen during preparation, dispensin gandadministration ofthese drugs .There areafew\ntypes ofmedication errors related toinjectable\ndrugs that are commonly reported to\nMedication Error Reporting System (MERS), for\nexample :incorrect dilution, incorrect route of\nadministration, incorrect infusion rate and\nincorrect diluent .Thus, promoting safe injection\npractices and establishment ofstandard for\ndilution and administration ofinjectable drugs\narecrucial toensure patient safety .\nEnsuring safer care forevery patient, every time,\neverywhere isthevision established byWHO as\nthegoals towards continuous improvements in\npatient safety and managing risks toprevent\nharm (particularly “avoidable harm” during\ntreatment and care) .Hence, medication safety\niseveryone’s responsibility soastomake the\nhealthcare system safer .This guideline aims to\nfacilitate the healthcare personnel inpreparing\nthedilutions ofdrugs which areavailable inthe\nMOH drug lists.The availability ofthis guideline\nwillassist intheexpansion ofquality clinical care\npharmacy services throughout MOH facilities .\nIwould like tocongratulate the editorial\ncommittee, accreditors and reviewers fortheir\nefforts and contributions inthe development\nofthis dilution guideline .Itishoped that this\nguideline would beauseful reference forallwho\nareinvolved inthedilution and administration of\ninjectable drugs inthehealthcare facilities .\nAllthebest andthank you.FOREWORD\nMdm A’tia Binti Hashim\nDirector\nPharmacy Practice & Development Division  \nPharmaceutical Services Programme\nMinistry ofHealth Malaysia"
    },
    {
        "page_number": 10,
        "text": "6DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nACKNOWLEDGEMENT\nSpecial thanks dedicated toeveryone who were involved directly orindirectly intheestablishment of\nthisguideline .\nThis guideline consumes enormous amount ofwork, time efforts and dedication .Thus,\nPharmaceutical Services Programme ,Ministry ofHealth would liketoextend ourutmost gratitude to\nallindividuals and organizations that had provided valuable input, advice and information forthis\nguideline .\nWearealso grateful fortheprovision ofexpertise and technical support inthedevelopment ofthis\nguideline .Hopefully, theinformation provided can lead totheimprovements inquality and safe\nmedication practice .\nREVIEWERS\n◆Mdm Phan HuiSieng\nSenior Principal Assistant Director  \nPharmacy Practice &Development Division  \nSarawak State Health Department◆Mdm Norafidah Binti Idris\nPharmacist  \nSerdang Hospital\n◆Mdm PohWeiYoon  \nPharmacist  \nSelayang Hospital◆Mdm NorMazni Binti Mohamad Tamyes\nPharmacist\nTengku Ampuan Rahimah Hospital\n◆Mdm Noor Liyana Binti Yusup\nPharmacist\nRantau Panjang Health Clinic◆Mr.Muhammad Faizal BinMaarof\nPharmacist\nTuanku Ampuan Najihah Hospital\n◆Mdm Merina AwKarLing\nPhar macist\nKuala Lumpur Hospital◆Mdm Ong SuHua\nSenior Principal Assistant Director  \nPharmacy Practice &Development Division  \nPharmaceutical Services Programme\nMinistry of Health"
    },
    {
        "page_number": 11,
        "text": "7DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\n◆Mdm Fajaratunur Binti A.Sani\nPharmacist\nJohor Bahru District Health Office◆Mr. Ahmad Ridza BinAhmad Nizam\nPharmacist\nTuanku Ampuan Najihah Hospital\n◆Mdm Nur Mariana Binti Ayub\nPharmacist  \nKajang Hospital◆Mdm Nurul Husna Binti Sodri\nPharmacist\nPharmacy Practice & Development Division  \nSelangor State Health Department\n◆Mdm Wong Jern Ni\nPharmacist\nShah Alam Hospital◆Mr. Anuar BinMohamad\nPharmacist  \nKajang Hospital\n◆Mdm Ummi Kalsum Binti Lambak\nPharmacist  \nMelaka Hospital◆Mdm Haidah Binti AbRahim\nNursing Matron\nTengku Ampuan Rahimah Klang Hospital\n◆Mdm Wong Siew Ling  \nNursing Matron  \nSelayang Hospital◆Mdm Kasidah Binti Kasran\nNursing Sister\nShah Alam Hospital\n◆Mdm Sharina Binti Mohd Redzuan\nNursing Sister  \nKajang HospitalA  C  CR  E  D  I  T  O  R  S"
    },
    {
        "page_number": 12,
        "text": "8DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nEDITORIALBOARD\nADVISOR\n◆Mdm A’tia Binti Hashim\nDirector\nPharmacy Practice & Development Division  \nPharmaceutical Services Programme\nMinistry ofHealth Malaysia\nEDITORIAL COMMITTEE\n◆Mdm Munira Binti Muhammad\nDeputy Director\nPharmacy Practice & Development Division  \nPharmaceutical Services Programme  \nMinistry ofHealth◆Mdm Norhayati Binti Musa\nSenior Principal Assistant Director  \nPharmacy Practice & Development Division  \nPharmaceutical Services Programme  \nMinistry ofHealth\n◆Mdm Siew LeeJin\nSenior Principal Assistant Director  \nPharmacy Practice & Development Division  \nPharmaceutical Services Programme  \nMinistry ofHealth◆Mdm Lee Shal Ling\nSenior Principal Assistant Director  \nPharmacy Practice & Development Division  \nPharmaceutical Services Programme  \nMinistry ofHealth\n◆Mdm Noor Syuhaidah Binti Radzuan\nPrincipal Assistant Director\nPharmacy Practice & Development Division  \nPharmaceutical Services Programme  \nMinistry ofHealth"
    },
    {
        "page_number": 13,
        "text": "9DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nABBREVIATION &ACRONYM DESCRIPTION\nBW body weight\nD10 10% dextrose\nD5 5% dextrose\ng gram\ngtt drops\nHCl hydrochloride\nHSD5 0.45% sodium chloride + 5% dextrose\nIM intramuscular\nIV intravenous\nkg kilogram\nL litre\nmax m axim um\nm cg microgram\nmg milligram\nml millilitre\nNS 0.9% sodium chloride\nNSD5 0.9% sodium chloride + 5% dextrose\nRT room temperature\nSC subcutaneous\nw/v weight over volume\nWFI water forinjectionA  B  B  R  E  V  I  A  T  I  O  N  S    &    A  C  R  O  N  Y  M  S"
    },
    {
        "page_number": 14,
        "text": "10DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAcyclovir Injection\nBrand Name Vaxcel®Acyclovir IVForInfusion (Strength: 250mg)\nReconstitution Reconstitute 1 vial (250mg) with 10ml WFI or NS to provide a solution  \ncontaining 25mg/ml.\nFurther Dilution IVinfusion\n■Dilute the required volume ofreconstituted solution with diluent\ntogive aconcentration not greater than 5mg/ml (0.5%w/v) for\nadministration byinfusion .\n■Forchildren and neonates, where itisadvisable tokeep thevolume\noffluid toaminimum, dilution isonthebasis of4mlreconstituted\nsolution (100mgacyclovir) added to20mlofinfusion fluid.\n■Foradult, infusion bags containing 100mlofinfusion fluid areused,\neven when this would give anacyclovir concentration substantially\nbelow 0.5%w/v.Thus, one 100mlinfusion bag may beused forany\ndose between 250mg and 500mg (10and 20mlofreconstituted\nsolution) butasecond bag must beused fordoses between 500mg\nand 1000 mg.\nDiluents\nNS\nAdministration IVinfusion\nAdminister byslow IVinfusion over 1hour.\nStorage &StabilityRT(<25 °C)\nAfter reconstitution 48hours\nAfter dilution 48hours\n*Protect from light.\n*Reconstituted ordiluted solutions SHOULD NOT BEREFRIGERATED.\nRemarks ■This infusion contains nopreservative .Should visible turbidity or\ncrystallization appear inthesolution before orduring infusion, the\npreparation should bediscarded .\n■Donotgive byIVbolus, IMorsubcutaneous route .\n■Beaware that too-rapid infusion may damage renal tubules .\nReferences 1.Product leaflet Vaxcel®Acyclovir IVForInfusion (Kotra Pharma (M)\nSdn.Bhd, Malaysia) .Revised date :2.4.2019 .\n2.Schull, P.D.,2009.McGraw-Hill’sIVDrug Handboo k.McGrawHill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 15,
        "text": "11DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAmikacin Injection\nBrand Name Apalin (Strength: 500mg/2ml)\nReconstitution Not required\nFurther Dilution IVinfusion\nAdd 500mg amikacin solution to100–200ml diluent.\nDiluents\nNS,D5\nAdministration IM\nIVinfusion\n■Adult :Administer slowly over 30–60minutes .\n■Infants :Administer slowly over 1–2hours .\nStorage &StabilityRT(25 °C) Fridge (4°C)\nAfter dilution 24hours 60days\nRemarks ■Slow IVinfusion may help toavoid neuromuscular blockade .\n■Donot physically premix amikacin injection orinfusion solutions\nwith other drugs atanypoint intheinfusion apparatus .\nReferences 1.Product leaflet Apalin (Duopharma (M)Sdn Bhd, Malaysia) .Revised\ndate :16.1.2012.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 16,
        "text": "12DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAmoxicillin & Clavulanate Injection\nBrand Name Clavam For Injection BP (Strength: 1.2g).\nContains: Amoxicillin 1gas sodium salt, Clavulanic acid 200mg as the  \npotassium salt.\nReconstitution Reconstitute 1vial(1.2g)with 20ml WFI (Final volume 20.9ml).\nFurther Dilution IVinfusion\nDilute thereconstituted solution to100ml diluent.\nDiluents\nNS,WFI\nAdministration Slow IV bolus\n■Administer slowly over 3–4minutes and within 20minutes of\nreconstitution .\n■Itmay beinjected directly into thevein orviaadrip tube .\nIVinfusion\nAdminister over 30–40minutes and complete within the time\nstated .\nStorage &StabilityRT(25°C) Fridge (5°C)\nAfter reconstitution 20minutes -\nAfter dilution 4hours 8hours\n*Any residual antibiotic solutions should bediscarded.\nRemarks ■The colour ofthereconstituted solution may range from acream\ncoloured solution toslight yellow/pale straw -coloured solution .\n■Not suitable forintramuscular administration .\n■Injection solution isless stable ininfusions containing glucose,\ndextrose orbicarbonate .\n■Should not bemixed with blood products, other proteinaceous\nfluids such asprotein hydrolysates orwith intravenous lipid\nemulsions .\nReferences Product leaflet Clavam For Injection BP(Alkem Laboratories Limited,\nIndia) .Revised date :April 2016 .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 17,
        "text": "13DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAmphotericin BInjection\nBrand Name Photericin BForInjection USP (Strength: 50mg)\nReconstitution ■Reconstitute 1vial(50mg) with 10mlofWFI.\n■Shake thevialimmediately until thecolloidal solution isclear .\nFurther Dilution IVinfusion\n■Further dilute with diluent toproduce the recommended\nconcentration of0.1mg/ml .\n■Final concentration should not exceed 0.1m g/m l forperipheral\ninfusion or0.25m g/ml forcentral infusion .\nDiluent\nD5\nAdministration IVinfusion\n■Administer byslow IVinfusion over 2 to6hours (depending onthe  \ndose).\n■Asingle IVtest dose (1mgin20mlofD5)administered over 20to\n30minutes may bepreferred .\nStorage &StabilityRT(25°C) Fridge\nAfter reconstitution 24hours 7days\nAfter dilution 24hours 2days\n*Protected from light\nRemarks ■Thepatient’s temperature, pulse, respiration, and blood pressure\nshould berecorded every 30minutes for2to4hours .\n■Rapid IVinfusion, over less than 1hour, particularly inpatients with\nrenal insufficiency, has been associated with hyperkalemia and\narrhythmias and should therefore beavoided .\n■The infusion solution (0.1mg/ml) isobtained byfurther dilution with\nD5ofpHabove 4.2.The pHofeach container ofdextrose injection\nshould beascertained before used .\n■Donotreconstitute with saline solutions .\n■An in-line membrane filter may beused for IVinfusion of\namphotericin B(the mean pore diameter ofthefilter should notbe\nless than 1micron) .\nReferences 1.Product leaflet Photericin BForInjection USP (Cipla LTD, India) .\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*Theinformation provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 18,
        "text": "14DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAmpicillin Injection\nBrand Name Kampibiotic Injection (Strength: 500mg)\nReconstitution IV\nDissolve 1vial(500mg) in10mlWFI.\nIM\nDilute 1vial(500mg) with 1.5mlWFI.\nFurther Dilution IVinfusion\nDilute with 50to100 mlNS(maximum concentration :30mg/ml) .\nDiluent\nNS\nAdministration Slow IV bolus\n■Administer slowly over 3to4minutes .\n■Donotexceed 100mg/minute .\nIntermittent IVinfusion\nAdminister over 15–30minutes.\nIM\nStorage &Stability Use immediately\nRemarks ■Beaware that too-rapid infusion may cause seizures .\n■Extemporaneous admixtures ofbeta -lactam antibacterials and\naminoglycosides may result insubstantial mutual inactivation .If\nthese administered concurrently, administered inseparate sites at\nleast 1hour apart .Donotmix them inthesame intravenous bag,\nbottle ortubing .\n■Ifampicillin isprescribed concurrently with anaminoglycoside, the\nantibiotics should not bemixed inthe syringe, intravenous fluid\ncontainer orgiving setbecause lossofactivity oftheaminoglycoside\ncanoccur under these conditions .\nReferences 1.Product leaflet Kampibiotic Injection (Karnataka Antibiotics &\nPharmaceuticals Limited, India) .Revised date :25.7.2017.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n3.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 19,
        "text": "15DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAmpicillin &Sulbactam Injection\nBrand Name Amsubac Injection (Strength: 1.5g)\nContains: Ampicillin 1000mg, Sulbactam 500mg\nReconstitution IV\n■Reconstitute 1vial(1.5g)with 3.2mlWFI.\n■Toensure complete dissolution, allow foaming todissipate topermit\nvisual inspection .\nIM\nReconstitute with 3.2mlWFI or0.5%lignocaine HCl.\nFurther Dilution IVinfusion\nFurther dilute to50–100ml diluent.\nDiluent\nNS\nAdministration Slow IV bolus\nAdminister slowly over am in im u m of3minutes .\nIVinfusion\nAdminister over 15–30minutes.\nIM\nAdminister bydeep IMinjection.\nStorage &Stability Not available\nRemarks ■Donotmix orgive through same I.V.line with aminoglycosides, as\nthis inactivates ampicillin/sulbactam .\n■Rapid infusion may cause seizures .\nReferences 1.Product leaflet Amsubac Injection (Karnataka Antibiotics &\nPharmaceuticals Limited, India) .Revised date :23.1.2018.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 20,
        "text": "16DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAnidulafungin Injection\nEraxis (Strength: 100mg)\nReconstitute 1vial(100mg) with 30mlWFI toprovide aconcentration of\n3.33mg/ml .The reconstitution time canbeupto5minutes .\nIVinfusion\nDilution Requirements ForAnidulafungin Administration\nOfWater ForInjection PresentationDose\nNumber of  \nVials\nRequired\nTotal  \nReconstitu ted  \nVolume  \nRequired\nInfusion  \nVolumeA\nTotal Infusion  \nVolumeB\nRate of\nInfusion\nMinimum  \nDuration of  \nInfusion\n100mg 1 30ml 100ml 130ml 1.4ml/minute 90minutes\n200mg 2 60ml 200ml 260ml 1.4ml/minute 180minutes\nAEither 9mg/ml (0.9%)sodium chloride forinfusion or50mg/ml (5%)\nglucose forinfusion .\nBInfusion solution concentration is0.77mg/ml .\nDiluents\nNS,D5\nIV infusion ONLY\nThe rate ofinfusion should not exceed 1.1mg/minute (equivalent to\n1.4ml/minute or84ml/hour when reconstituted and diluted per\ninstructions) .\nRT(25°C) Fridge (Frozen)\nAfter reconstitution 24hours -\nAfter dilution 48hours 72hours\n*For single useonly\n■Anaphylactic reactions, including shock, have been reported ;\ndiscontinue useand appropriate treatment administered .\n■Infusion -related adverse events have been reported with\nanidul afungin, including rash, urticaria, flushing, pruritus, dyspnea,\nbronchospasm andhypotension .\n■Infusion -related adverse events are infrequent when the rate of\nanidulafungin infusion does notexceed 1.1mg/minute .\n■Donotgive asIVbolus .Brand Name\nReconstitution\nFurther Dilution &  \nAdministration\nStorage &Stability\nRemarks\nReferences1.Product leaflet Eraxis (Pharmacia and Upjohn Company, USA) .\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 21,
        "text": "17DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nArtesunate Injection\nBrand Name Artesun Powder For Injection (Strength: 60mg)\nReconstitution ■Reconstitute 1vial (60mg) with provided diluent (5%sodium\nbicarbonate solution) .\n■Shake thevialfor2–3minutes and wait until completely dissolved\nand aclear solution should emerge .\nFurther Dilution Dilute the reconstituted solution (1ml)with diluent toproduce the\nrequired concentration .\nRoute of Diluent Total Volume Final  \nAdminist ration (NSorD5) Concentration\nIV 5ml 6ml 10mg/ml\nIM 2ml 3ml 20mg/ml\nAdministration Slow IV bolus\nAdminister therequired dose slowly atarate of3–4ml/minute .\nIM\nStorage &Stability Use immediately\nRemarks ■Donotuseinintravenous drip.\n■Discard ifsolution notclear .\nReferences Product leaflet Artesun Powder ForInjection (Guilin Pharmaceutical\nCo.Ltd,China) .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 22,
        "text": "18DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAzithromycin Injection\nVaxcel® Azithromycin IV For Infusion (Strength: 500mg)\nReconstitute 1vial (500mg) with 4.8mlWFI toobtain afinal\nconcentration of100mg/ml .\nIVinfusion\nDilute the reconstituted solution tothe required concentration as\nbelow :\nAmount of  \nreconstitu ted  \nsolution (ml)Final infusion solution  \nconcentration\n(mg/ml)Amount ofdiluent  \n(ml)\n5 1 500\n5 250\nDiluents\nNS,D5\nIVinfusion\nAnIVdose of500mgazithromycin should beinfused foram in im um\nduration of1hour .\nRT Fridge ( 2°C-8°C)\nAfter reconstitution 24 hours (25±2○C) -\nAfter dilution 24 hours (<25○C) 7days\n■Donotadminister asanIVbolus oranIMinjection .\n■Other intravenous substances, additives ormedications should not\nbeadded tointravenous azithromycin orinfused simultaneously\nthrough thesame IVline.Brand Name\nReconstitution\nFurther Dilution\nAdministration\nStorage &S tability\nRemarks  \nReferences Product leaflet Vaxcel®Azithromycin IVFor Infusion, (Kotra Pharma\n(M)Sdn.Bhd, Malaysia) .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.2\n1 over 3hours\n2 over 1hourConcentration (mg/ml) Rate  of infusion"
    },
    {
        "page_number": 23,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nBenzathine Penicillin Injection\nBrand Name Benzapen Sterile Penicillin GBenzathine USP (Strength :2.4Mega\nUnits)\nReconstitution Reconstitute with 8mlofWFI.\nFurther Dilution Not required\nAdministration IMonly\n*Toavoid sciatic nerve damage, infants and small children should not\nbeinjected into the upper outer quadrant ofthe buttock except in\nspecial cases e.g.inthepresence ofextensive burns .\nStorage &Stability Use immediately\nRemarks ■Patient should bealerted tothe potential occurrence ofallergic\nreactions and instructed toreport them .\n■Patient should beobserved for30minutes after drug administration\nforany allergic reactions .\n■Must notbeinjected subcutaneously, intravenously orintrathecally\norinstilled into body cavities .\nReferences Product leaflet Benzapen Sterile Penicillin GBenzathine USP 2.4MU\n(Karnataka Antibiotics &Pharmaceuticals Limited, India) .Revised date :\n13.7.2009 .\n19\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 24,
        "text": "20DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nBenzylpenicillin Injection\nBrand Name Bepen Injection (Strength :1MU(600mg), 5MU(3g))\nReconstitution ■Reconstitute 1MUvial(600mg) with 2mlormore WFI immediately\nbefore use.\n■Reconstitute 5MU vial (3g)with 10mlormore WFI immediately\nbefore use.\nFurther Dilution Intermittent IVinfusion\nFurther dilute in50–100mldiluent .\nContinuous IVinfusion\nFurther dilute in1000–2000 mldiluent .\nDiluent\nNS\nAdministration IM\nAlternate sites should beused forrepeated injections.\nIntermittent IVinfusion\n■Administer over 1–2 hours (adults).\n■Administer over 15to30minutes (children and infants).\nContinuous IVinfusion\n■Administer over 24 hours.\n■Preferred foradministration oflarge doses.\nStorage &StabilityRT(30°C±2°C)Fridge (2°C-8°C)\nAfter reconstitution 2days 6days\n*Reconstituted solutions ofbenzylpenicillin sodium BPareintended\nforimmediate administration .\nRemarks ■Should beadministered separately with solutions that contain\nmetal ions.\n■Too-rapid infusion may cause electrolyte imbalance orseizures .\nReferences 1.Productleaflet Bepen Injection (Karnataka Antibiotics &\nPharmaceuticals Limited, India) .Revised date :14.2.2017.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 25,
        "text": "21DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCaspofungin Acetate Injection\nCancidas®For Injection (Strength: 50mg, 70mg)\nBring therefrigerated vialtoroom temperature .\n50mgvial\nReconstitute 1vial (50mg) with 10.5mlofNSorWFI toobtain a\nconcentration of5.2mg/ml .Brand Name\nReconstitution\nFurther Dilution70mgvial\nReconstitute 1vial (70mg) with 10.5mlofNSorWFI toobtain a\nconcentration of7.2mg/ml .\nDose* Volume of  \nreconstitu ted  \nsolution for  \ntransfer to IV  \nbag/bottleTypical  \npreparation  \n(reconstituted  \nsolution added \nto 100ml) final  \nconcentration\n70mg (from one 70mg vial)  \n(Dilute intwo bags of100ml) **5m l in each  \n100ml IVbag/  \nbottle0.33mg/ml\n50mg (from one 50mg vial) 10ml 0.45mg/ml\n35mg formoderate hepatic\ninsufficiency (from one 70mg vial)5ml 0.33mg/ml\n35mg formoderate hepatic\ninsufficiency (from one 50mg vial)7ml 0.33mg/ml\n*10.5mlshould beused forreconstitution ofallvials .\n**Dilute 5mlofthereconstituted vialina100mlIVbag/bottle and the\nother 5mlinasecond 100mlIVbag/bottle .\nNote:\nPaediatric patients (≥12months old):Dilute reconstituted solution\n(volume equal tothecalculated dose) toanIVbag orbottle containing\n250mlofdiluent orareduced volume ofdiluent, nottoexceed afinal\nconcentration of0.5mg/ml .\nDiluents\nNSor0.45% Sodium Chloride (Paediatric patients)Depends ondose required\nPreparation ofthePatient Infusion Solutions inAdults :"
    },
    {
        "page_number": 26,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nIV infusion ONLY\n■Administer byslow IVinfusion over approximately 1hour .\n■Fora70mgdose, administer each ofthebags orbottles sequentially\nover 30minutes, foratotal infusion time ofapproximately 1hour .\nRT(<25°C) Fridge (2°C-8°C)\nAfter reconstitution 24hours -\nAfter dilution 24hours 48hours\n*The lyophilized compact powder invials should bestored at2○C–8○C.\n■Donotuseanydiluents containing dextrose (-D-glucose) .\n■Donotmix orco-infuse with anyother medications .\n■Visually inspect thereconstituted solution forparticulate matter or\ndiscoloration during reconstitution and prior toinfusion .Donotuse\nifthesolution iscloudy orhasprecipitated .Administration\nStorage &Stability\nRemarks\nReferencesProduct leaflet Cancidas®For Injection (Laboratories Merch Sharp &\nDohme -Chibret, France) .Revised date :September 2014 .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.\n22"
    },
    {
        "page_number": 27,
        "text": "23DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCefazolin Injection\nBrand Name Cefazolin Sandoz®DrySubstance ForInfusions (Strength: 1g)\nReconstitution Slow IV or IVinfusion\nReconstitute 1vial(1g)with 4mlNSorWFI.\nIM\nReconstitute 1vial(1g)with 4ml0.5%lidocaine solution .\nFurther Dilution IVinfusion\nDilute in50–100mldiluent.\nDiluent\nNS\nAdministration Slow IV bolus\nAdminister slowly over 3–5minutes. (Uptoadose 1gcefazolin).\nIVinfusion\nAdminister doses >1gover 20–30minutes.\nIM\nInject into amajor muscle mass.\nStorage &Stability Use immediately\nRemarks Donotmix insame infusion with aminoglycoside, because both drugs\nmay beinactivated .\nReferences 1.Product leaflet Cefazolin Sandoz®Dry Substance For Infusions\n(Biochemiestr, Austria) .\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 28,
        "text": "24DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCefepime Injection\nBrand Name Cefmex Powder ForInjection (Strength: 1g)\nReconstitution IV\nReconstitute 1vial(1g)with 10mlofdiluent (approximate concentration\n90mg/ml) .\nIM\nReconstitute 1vial(1g)with 3mlofdiluent (approximate concentration\n230mg/ml) .\nDiluents\nWFI, D5,NS\nFurther Dilution IVinfusion\nDilute toavolume of50–100mlofdiluent .\nDiluents\nD5,NS\nAdministration Slow IVbolus\nAdminister slowly over 3–5minutes .\nIVinfusion\nAdminister over 30minutes .\nIM\nAdminister through deep IMinjection into alarge muscle mass .\nStorage &StabilityFridge (2°C-8°C)\nAfter reconstitution 48hours\nAfter dilution 48hours\n*Intravenous :Cefepime iscompatible atconcentration of1–40mg/ml\nwhen mixed with diluents .\nRemarks Parenteral drugs should beinspected visually forparticulate matter\nbefore administration, and notused ifparticulate matter ispresent .\nReferences Product leaflet Cefmex Powder ForInjection (Duopharma (M)Sdn.Bhd,\nMalaysia) .Revised date :14.10.2014.\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 29,
        "text": "25DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCefoperazone Injection\nBicafar (Strength: 1g)\nIV\n■Reconstitute 1vial(1g)with 5mlofD5,NSD 5,NSorWFI.\n■Forcontinuous IVinfusion, dissolve each gram in5mlWFI.\nIM\nWFI may beused toprepare cefoperazone forIMinjection .However,\nwhen concentrations of≥250m g/m l tobeadministered, alidocaine\nsolution should beused .A2-STEP dilution process isrecommended .\nVial  \n(g)Final  \nCefoperazone  \nConcentration  \n(mg/ml)Step 1 :   \nVolume  \nof WFI  \n(ml)Step 2:  \nVolume of  2%\nLidocaine \n(ml)Withdrawable  \nVolume (ml)\n1 250\n3332.6\n1.80.9\n0.64\n3\n*There issufficient excess present toallow for withdrawal and\nadministration ofthestated volume .\nSlow IVbolus\nAdminister slowly over aperiod ofnoless than 3–5minutes .\nIntermittent IVinfusion\nAdminister over aperiod of15minutes –1hour.\nIM\nDeep IMinjection into thelarge muscle mass ofgluteus m axim um or\nanterior thigh .\nRT (15°C-25°C) Fridge ( 2°C-8°C)\nAfter reconstitution 24hours 5days\n*A solution of300mg/ml\nSolution ofcefoperazone and aminoglycoside should not bedirectly\nmixed since there isaphysical incompatibility between them .Brand Name\nReconstitution\nFurther Dilution\nAdministration\nStorage &S tability\nRemarks  \nReferencesProduct leaflet Bicafa r(Duopharma (M) Sdn Bhd, Malaysia) .Revised\ndate :14.8.2012 .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.IV(maximum dose of2g/day)\nDilute inappropriate diluent togive afinal concentration of100mg/ml .\nIntermittent IVinfusion\nDilute thereconstituted solution with 20–100mlofdiluent .\nDiluents\nD5,NSD 5,NS"
    },
    {
        "page_number": 30,
        "text": "26DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCefoperazone & Sulbactam Injection\nBrand Name Vaxcel® Cefobactam Injection (Strength: 1g)\nContains: Cefoperazone 500mg and Sulbactam 500mg\nReconstitution &  \nFurther DilutionIV\n■Reconstitute 1vial(1g)with 3.4mlWFI, D5orNS.\nIntermittent IVinfusion\nDilute thereconstituted solution to20ml with thesame solution.\nIM\nForaconcentration ofcefoperazone of≥250mg/ml, reconstitute 1vial\n(1g)with 3.4mlsterile WFI and further dilute with 2%lidocaine to\nobtain solutions containing upto250mg cefoperazone and 125mg\nsulbactam/ml inapproximately 0.5%lidocaine hydrochloride solution .\nAdministration Slow IV bolus\nAdminister slowly over aminimum of3minutes .\nIntermittent IVinfusion\nAdminister over 15–60minutes .\nIM\nStorage &StabilityRT(<25°C)\nAfter reconstitution 24hours\nRemarks Solutions ofsulbactam/cefoperazone and aminoglycosides should\nnot bedirectly mixed, since there isaphysical incompatibility\nbetween them .\nReferences Product leaflet Vaxcel®Cefobactam Injection (Kotra Pharma (M)Sdn.\nBhd, Malaysia) .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.Maximum Final \nConc. (mg/ml)Equiv. Dosage of \nSulbactam + \nCefoperazone (g)Total \nDosage (g)Volume of \ndiluent\n1 0.5 + 0.5 3.4 125 + 125"
    },
    {
        "page_number": 31,
        "text": "27DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCefotaxime Injection\nBrand Name Rekaxime Injection (Strength: 500mg, 1g)\nReconstitution ■Reconstitute 1vial(500mg) with 2mlofWFI.\n■Reconstitute 1vial(1000 mg) with 4mlofWFI.\nFurther Dilution IVinfusion\n■Short infusion\nDilute in40mlofWFI or10% glucose solution.\n■Continuous drip\nDilute in100ml ofisotonic saline orglucose solution.\nDiluents\nNS, D5, D10 (for shor t infusion)\nAdministration Slow IV bolus\nAdminister slowly over aperiod of3–5minutes.\nShort infusion\nInfused inapproximately 20minutes.\nContinuous drip\nInfuse over 50–60minutes.\nIM\nInject deep into thegluteus muscle .Not toinject >4mlinto either side.\nIfdaily dose exceeds 2g,IVinjection ispreferred .\nStorage &StabilityRT(<25°C)\nCefotaxime Solutions 24hours\n*Cefotaxime solutions should beadministered assoon asthey have\nbeen prepared .\nRemarks ■Incompatible with alkaline solutions such assodium bicarbonate\nand also incompatible with hetastarch sodium chloride .\n■Admixture ofß-lactam antibacterials, aminoglycosides and\nmetronidazole may result insubstantial inactivation .Should not\nbeadministered concurrently/mixed/injected atthe same site as\ncefotaxime .\n■Apale yellowish solution does not mean animpairment ofthe\nantibiotic efficacy .\n■IVbolus given over less than 1minute have caused life-threatening\narrhythmias .\nReferences 1.Product leaflet Rekaxime Injection (Duopharma (M) Sdn Bhd,\nMalaysia) .Revised date :19.11.2013.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 32,
        "text": "28DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCeftazidime Injection\nCefatum Injection (Strength: 1g, 2g)\nMay beconstituted with WFI or,forIMinjection, with 0.5%lignocaine .\nVialSize Diluent Amount of  \ndiluent tobe  \naddedApproximate  \nConcentration  \n(mg/ml)\n1g (10ml vial) IM 0.5% lignocaine 3ml 260\nIV WFI 10ml 90\n2g (20ml vial) IV WFI 170\nIntermittent IVinfusion\nDilute in100ml ofdiluent.\nDiluents\nNS, D5\nIntermittent IVinfusion\nInfuse over 30minutes.\nIM\nAdminister bydeep IMinto alarge mass muscle.\nDiluent RT  \n(<25°C)Fridge\n( 2°C-8°C)\nAfter reconstitution WFI 12hours 7days\n0.5% lignocaine 6hours 4days\nAfter dilution - *12hours *7days\n*At concentration 1-40 m g/m lBrand Name\nReconstitution\nFurther Dilution\nAdministration\nStorage &Stability\nRemarks\nReferences■Sodium bicarbonate injection isnotrecommended asadiluent .\n■Solutions range from light yellow toamber depending on\nconcentration, diluent and storage conditions used .W ithin the\nstated recommendations, product potency isnotadversely affected\nbysuch colour variations .\n■Individual doses inexcess of1gshould beadministered intravenously .\n■The admixture ofbeta -lactam antibacterials (penicillins and\ncephalosporins) and aminoglycosides may result insubstantial\nmutual inactivation .\n1.Product leaflet Cefatum Injection (Duopharma (M) Sdn Bhd,\nMalaysia) .Revised date :21.6.2014.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n3.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.Slow IV bolus\nAdminister slowly over 3–5minutes.10ml"
    },
    {
        "page_number": 33,
        "text": "29DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCeftriaxone Injection\nUnocef Injection (Strength: 500mg, 1g)\nIM\n■WFI, NS, D5, 1%lidocaine solution (without ephinephrine)\nVial Dosage Size Amount of Diluent tobeAdded\n250mg/ml 350mg/ml\n500mg 1.8ml 1ml\n1g 3.6ml 2.1ml\n*Ifrequired, more dilute solutions could beutilized .\n*A350mg/ml concentration isnot recommended forthe 250mgvial\nsince itmay notbepossible towithdraw theentire contents .\nIV\n■WFI, NS,D5\nVialDosage Size Amount ofDiluent tobe  \nAdded\n500mg 4.8ml\n1g 9.6ml\nIVinfusion\nDilute thereconstituted solution to50or100ml diluent.\nDiluents\nNS,D5\nIVinfusion\nAdminister over aperiod of30minutes .Concentration between\n10-40mg/ml arerecommended, lower concentration may beused if\ndesired .\nIM (for Gonorrhoea, Chancroid)\n■Administer deep IMinto large muscle mass.\n■Doses >1gshould bedistributed between two injection sites.Brand Name\nReconstitution\nFurther Dilution\nAdministration"
    },
    {
        "page_number": 34,
        "text": "30DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nIM\nDiluentConcentration  \n(mg/m l) RT(25○C) Fridge (4○C)\nWFI 100 3days 10days\n250, 350 24hours 3 days\nNS 100 3days 10days\n250, 350 24hours 3days\nD5 100 3days 10days\n250, 350 24hours 3days\n1%Lidocaine solution  \n(without ephinephrine)100 24hours 10days\n250, 350 24hours 3days\nIV solutions stored in glass or PVCcontainers\nDiluent Concentration  \n(mg/m l)RT(25°C) Fridge (4°C)\nWFI 10,20,40 3days 10days\nNS 10,20,40 3days 10days\nD5 10,20,40 3days 10days\n■Diluents containing calcium, such asRinger’s solution or\nHartmann’s solution, are not tobe used toreconstitute\nceftriaxone vials orto further dilute areconstituted vial for\nintravenous administration because aprecipitate canform .\n■Ceftriaxone must notbeadministered simultaneously with calcium -\ncontaining intravenous solutions, including continuous calcium -\ncontaining infusions such asparenteral nutrition viaY-site.\n■Inpatients other than neonates, ceftriaxone and calcium -containing\nsolutions may beadministered sequentially toone another ifthe\ninfusion lines are thoroughly flushed between infusions with\ncompatible fluid.Storage & Stability\nRemarks\nReferences 1.Product leaflet Unocef Injection (Duopharma (M)Sdn Bhd, Malaysia) .\nRevised date :2.10.2013.\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.After reconstitution, protection from normal light isnot necessary .\nStability varies with concentration and diluents used :The colour of\nsolutions ranges from light yellow toamber, depending onthelength\nofstorage, concentration and diluent used ."
    },
    {
        "page_number": 35,
        "text": "31DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCefuroxime Injection\nBrand Name Pharmaniaga Cefuroxime Injection (Strength: 750mg, 1.5g)\nReconstitution IM\nReconstitute 750mgvialwith 3mlofWFI.\nIV\n■Reconstitute 750mgvialwith 8mlofWFI.\n■Reconstitute 1.5gvialwith 16mlofWFI.\nFurther Dilution Intermittent IVinfusion\nW ithdraw therequired dose and add to50–100ml ofdiluent.\nDiluents\nNS,D5\nAdministration Slow IVbolus\nAdminister slowly over 3–5minutes .\nIntermittent IVinfusion\nAdminister over 30minutes .\nIM\nInject deep IMinto large muscle mass (such asgluteus orlateral\npart ofthethigh) .\nStorage &StabilityRT Fridge (2°C–8°C)\n- 2hours  \n24hours -\nRemarks ■Donotmix with sodium bicarbonate .\n■Donot mix insame infusion with aminoglycoside, because both\ndrugs may beinactivated .\n■Before injecting intramuscularly, aspiration isnecessary toavoid\ninadvertent injection into ablood vessel .\nReferences 1.Product leaflet Pharmaniaga Cefuroxime Injection (Pharmaniaga\nManufacturing Berhad, Malaysia) .\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.After reconstitution\nAfter dilution"
    },
    {
        "page_number": 36,
        "text": "32DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nClindamycin Injection\nTidact Injection (Strength: 300mg/2ml)  \nNot required\n■Must beDILUTED prior toIVadministration .\n■Toprepare initial dilution forIVuse:\nDose (mg) Diluent (ml) Duration of Administration\n300 50 10minutes\n600 50 20minutes\n900 100 30minutes\n1200 100 40minutes\n*Maximum final concentration :18m g/m l\n*Infusion rates should notexceed 30mg/minute\nDiluents\nNS,D5\nToMaintain Serum  \nClindamycin LevelsRapid Infusion Rate Main tenance  \nInfusion Rate\nAbove 4mcg/ml 10mg/minute\nfor 30minutes0.75 mg/minute\nAbove 5mcg/ml 15 mg/minute\nfor 30minutes1mg/minute\nAbove 6mcg/ml 20mg/minute\nfor 30minutes1.25mg/minute\nIM\n■Single IMInjection should notexceed 600 mg.Brand Name  \nReconstitution\nFurther Dilution\nAdministration\nStorage &Stability  \nRemarks\nReferences■Clindamycin is physically incompatible with ampicillin,\ndiphenyldantoin ,barbiturates, aminophylline, calcium gluconate\nand magnesium sulphate .\n■IVadministration should notbegiven undiluted orasIVbolus .\n■Rare instances ofcardiopulmonary arrest and hypotension have\nbeen reported following toorapid intravenous administration .\n■Contains benzyl alcohol, should beavoided inchildren under 2years\nofage and nottobeused inneonates .\n1.Product leaflet Tidact Injection (Yung Shin Pharmaceutical Ind.Co.,Ltd,\nTaiwan) .\n2.Gray, A.,Wright, J.,Goodey, V.andBruce, L.,2011.Injectable Drugs Guide .\nPharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.IVinfusion\n■Donotadminister more than 1200 mginasingle 1hour infusion .\n■May beadministered asasingle rapid infusion onthefirst dose and\nfollowed bycontinuous IVinfusion, asfollows :\nNot available"
    },
    {
        "page_number": 37,
        "text": "33DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nCloxacillin Injection\nCloxabiotic Injection (Strength: 250mg, 500mg)\nThe reconstituted solution must beshaken well before use.\nFillSize  \n(mg)Volume of  \nDiluent Added  \n(ml)Withdrawable  \nVolume\n(ml)Nominal  \nConcentration  \n(mg/ml)\nIM (Use WFI)\n250 1.9 2 125\n500 1.7 2 250\nIV Injection (Use WFI)\n250 4.9 5 50\n500 4.8 5 100\nIVinfusion\nReconstitute 1vialin5mlofWFI.\nSlow IVbolus\n■Administer into avein either directly orviaadrip-tube over aperiod\nof3to4minutes .\n■More rapid administration may result inconvulsive seizures .\nIVinfusion\nInfused over 30to40minutes .\nIM\nRT(≤25°C) Fridge (2°C-8°C)\nUpto48hours\n*Solution forinjection should befreshly prepared.\n*Discard unused portion.Brand Name\nReconstitution\nFurther Dilution\nAdministration\nStorage &Stability\nRemarks\nReferences■Ifcloxacillin isprescribed concurrently with anaminoglycosides,\nthe two antibiotics should not bemixed inthe same syringe,\nintravenous fluid container orgiving setbecause ofloss ofactivity\noftheaminoglycosides canoccur under these conditions .\n■Cloxacillin injection should notbemixed with proteinaceous fluids\nsuch asprotein hydrolysates, blood orplasma, orwith intravenous\nlipid emulsions .\nProductleaflet Cloxabiotic Injection (Karnata kaAntibiotics &\nPharmaceuticals Limited, India). Revised Date: 12.2.2018.\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.IVinfusion\nDilute thereconstituted solution in125ml to250ml ofdiluent toobtain\nafinal concentration of1–2mg/ml.\nDiluent\nNS\nUse within 30minutes\nof  preparationAfter  reconstitution"
    },
    {
        "page_number": 38,
        "text": "34DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nErtapenem Injection\nBrand Name Invanz® Injection ( Strength: 1g)\nReconstitution IVinfusion\nReconstitute 1vial(1g)with10mlsterile WFI, NSorbacteriostatic WFI.\nIM\n■Reconstitute 1vial(1g)with 3.2mlof1%or2%lidocaine HClinjection\n(without epinephrine) .\n■The reconstituted solution should notbeadministered intravenously .\nFurther Dilution IVinfusion\nPatients 13 years of age andolder\nDilute reconstituted drug to50ml ofNS.\nPatients 3 months to 12 years ofage\nW ithdraw avolume equal to15mg/kg ofbody weight (not toexceed\n1g/day) and dilute in0.9%Sodium Chloride Injection toafinal\nconcentration of20mg/ml orless.\nDiluent\nNS\nAdministration IVinfusion\nAdminister the diluted solution over 30minutes and complete the\ninfusion within 6hours ofreconstitution .\nIM\nAdminister thereconstituted solution bydeep IMinjection into alarge\nmuscle mass (e.g.gluteal muscle orlateral part ofthethigh) .\nStorage &StabilityRT(25°C) Fridge (5°C)\nAfter reconstitution IV:6hours 24hours and usewithin\nIM: usewithin 4 hours after\n1 hour removal from refrigeration\nAfter dilution IV:6hours 24hours and usewithin\n4 hours after  \nremoval from refrigeration\nRemarks ■Must bereconstituted and diluted prior toadministration .\n■Donotusediluents containing dextrose .\n■Donotmix orco-infuse Invanz®with other medications .\n■The diluted solution ofErtapenem should notbefrozen .\nReferences 1.Product leaflet Invanz®Injection (Laboratories Merck Sharp &\nDohme -Chibret ).Revised date :August 2015 .\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 39,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\n35Erythromycin Lactobionate Injection\nBrand Name Eritrotex Injection (Strength: 500mg)\nReconstitution Reconstitute 1vial (500mg) with 10mlWFI toobtain final concentration\n50mg/ml .\nFurther Dilution IVinfusion\nDilute the reconstituted solution with not less than 100mlofdiluent\ntoafinal concentration of1–5mg/ml .\nDiluents\nNS,D5\nAdministration Intermittent IVinfusion\nAdminister thediluted solution over 60minute severy 6hours .\nContinuous IVinfusion\nAdminister thediluted solution over 24hours .\nStorage &Stability The injection should befreshly prepared and unused portion should be\ndiscarded .\nRemarks ■Erythromycin should not bereconstituted with inorganic salt\nsolution .Use only WFI.\n■Donotadminister IVpush orbolus .\n■Rapid infusion ismore likely tobeassociated with arrhythmias or\nhypotension .\nReferences 1.Product leaflet Eritrotex Injection (Fisiopharma S.r.L,Italy) .Revised\ndate :November 2008 .\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 40,
        "text": "36DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nGanciclovir Injection\nBrand Name Cymevene® (Strength: 500mg)\nReconstitution ■Reconstitute 1vial(500mg) with 10mlWFI.\n■The vialshould beshaken todissolve thedrug .\n■Reconstituted solution should beinspected forparticulate matter\nprior toproceeding with admixture preparation .\nFurther Dilution IVinfusion\n■W ithdraw therequired dose and dilute to50–250mlofcompatible\ninfusion fluid.\n■The final concentration must notexceed 10mg/ml .\nDiluents\nNS,D5\nAdministration IVinfusion\n■Administer over 60minutes viaalarge peripheral orcentral vein\n(adequate blood flow isessential toensure rapid dilution and\ndistribution) .\n■Infusion concentration greater than 10mg/ml arenotrecommended .\nStorage &StabilityRT Fridge (2°C-8°C)\nAfter reconstitution 12hours Itshould notbe\nrefrigerated\nAfter dilution Use immediately 24hours\nRemarks ■Donotusebacteriostatic water forinjection containing parabens in\nsolution since these areincompatible and may cause precipitation .\n■The prepared solution should notbemixed with other IVproducts .\n■Itisapotential teratogen and carcinogen inhumans, caution should\nbeobserved inthehandling ofganciclovir .Avoid inhalation ordirect\ncontact ofthepowder contained inthevials ordirect contact ofthe\nreconstituted solution with theskin ormucous membranes .\n■Donotgive byIVbolus orbyIMorSCroute .\nReferences 1.Product leaflet Cymevene®(F.Hoffman -LaRocge Ltd.Basel) .\nRevised date :June 2010 .\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 41,
        "text": "37DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nGentamicin Injection\nBrand Name Garasent (Strength: 80mg/2ml)\nReconstitution Not required\nFurther Dilution IVinfusion\n■Dilute theprescribed dose in100–200mlofdiluent .\n■Final infusion concentration should notexceed 1mg/ml .\nDiluents\nNS,D5\nAdministration IM\nSlow IV bolus\nAdminister slowly over 2to3minutes.\nIVinfusion\nAdminister thediluted solution over 20–30minutes.\nStorage &StabilityFridge (2°C-8°C)\nAfter dilution 24hours\nRemarks ■Should beused with caution inpatients with impaired renal function\n(including elderly and premature infants) .\n■IVadministration isgenerally reserved forspecial indications and\nmay beused when theIMroute isnotfeasible, e.g.patients inshock,\nwith haemorrhagic disorders, severe burns orreduced muscle mass .\nReferences 1.Product leaflet Garasent (Duopharma (M) Sdn Bhd, Malaysia) .\nRevised date :16.1.2012.\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 42,
        "text": "38DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nImipenem & Cilastatin Injection\nBrand Name Imipenem /Cilastatin Kabi Powder ForSolution ForInfusion  \nContains: 500mg Imipenam and 500mg Cilastin\nReconstitution ■Reconstitute 1vialwith 10mlofdiluent tothecontainer .\n■Shake well and transfer theresulting mixture totheinfusion solution\ncontainer .\n■Repeat with anadditional 10mlofinfusion solution toensure\ncomplete transfer ofcontainer contents totheinfusion solution .\n■The resulting mixture should beagitated until aclear solution is\nobtained .\nFurther Dilution ■Dilute thereconstituted solution to100ml ofdiluent.\n■Final infusion concentration isapproximately 5mg/ml.\nDiluents\nNS,D5\nAdministration IV infusion ONLY\n■Doses≤500mg/500mg:\nAdminister diluted solution over 20–30minutes .\n■Doses >500mg/500mg:\nAdminister diluted solution over 40–60minutes .\nStorage &StabilityRT(30°C) Fridge (5°C)\nAfter reconstitution 4hours 24hours\nAfter dilution 4hours 24hours\nRemarks ■Should notbereconstituted indiluents containing lactate .\n■Inpatients who develop nausea during the infusion, the rate of\ninfusion may beslowed .\n■Donotgive bydirect IVinjection .\nReferences 1.Product leaflet Imipenem /Cilastatin Fresenius Kabi Powder For\nSolution ForInfusion (Facta Farmaceutical S.p.A,Italy) .Revised date :\nNovember 2015 .\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 43,
        "text": "39DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nMeropenem Injection\nBrand Name Nuronem Injection (Strength: 500mg, 1g)\nReconstitution Reconstitute 1vial (500mg) with 10mlWFI (5mlWFI per 250mg\nmeropenem) toobtain afinal concentration of50mg/ml .\nFurther Dilution IVinfusion\nDilute reconstituted solution with 50–200ml ofdiluents.\nDiluent s\nNS,D5\nAdministration Slow IV bolus\nAdminister slowly over 5 minutes.\nIVinfusion\nAdminister over 15–30minutes.\nStorage &StabilityRT(25°C) Fridge (4°C)\nAfter dilution 8hours (NS) 48hours (NS)  \n3hours (D5) 14hours (D5)\n*Reconstituted and diluted solution ofmeropenem should not be\nfrozen .\nRemarks ■Should notbemixed with oradded toother drugs .\n■Allvials forsingle useonly.\nReferences 1.Product leaflet Nuronem Injection (Ranbaxy Lab.Limited, India) .\nRevised date :August 2009 .\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs\nGuide .Pharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 44,
        "text": "40DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nMicafungin Injection\nMycamine®Powder ForSolution ForInfusion (Strength: 50mg)\n■Reconstitute 1vial(50mg) with 5mlofNSorD5(taken from a100ml\nbag/bottle) byslowly injected into each vialalong the side ofthe\ninner wall.\n■Rotate thevialgently .Donotshake .\n■Minimize theamount offoam generated .\nPreparation Of Solution ForInfusion:\nDose Vials to  be\nusedVolume \nof  NS or \nD5to  be \nadded  \npervialVolume  \n(concentration)  \nofreconstituted \npowderFinal  \nconcentration  \nof standard  \ninfusion\n(made up to\n100m l)\n50mg 1 x 50mg 5ml Approx. 5ml  \n(10mg/ml)0.5mg/ml\n100mg 2 x  50mg 5ml Approx. 10ml  \n(10mg/ml)1m g/m l\n150mg 3 x  50mg 5ml Approx. 15ml  \n(10mg/ml)1.5mg/ml\n200mg 4 x 50mg 5ml Approx. 20ml  \n(10mg/ml)2m g/m l\n■Theinfusion bag/bottle containing thediluted infusion solution should\nbeinserted intoaclosable opaque bagforprotection from light.\nDiluents\nNS,D5\nRT(30°C)\nAfter reconstitution 24hours\nAfter dilution6hours\n(Intransfusion bag without light protection)\n24hours\n(Intransfusion bag with light protection)Brand Name\nReconstitution\nFurther Dilution\nAdministration\nStorage &Stability\nRemarks\nReferencesThe concentrate should beused immediately forfurther dilution .This\nproduct isforsingle useinone patient only.Discard anyresidue .\n*The information provided inthis guideline may beused asgeneral reference only. Please refer  \ntothecurrent product inserts forrelevant brand used infacility.■Allofthe reconstituted concentrate should bewithdrawn from\neach vialand returned totheinfusion bag/bottle from which itwas\noriginally taken .\nIVinfusion ONLY\n■Anexisting IVlineshould beflushed with NSprior toinfusion .\n■Administer thereconstituted and diluted solution over approximately\nonehour .\n*when reconstituted with NSorD5\nProduct leaflet Mycamine ®Powder For Solution For Infusion\n(Astellas Pharma Tech Cp.Ltd, Japan) .Revised date :July 2013 ."
    },
    {
        "page_number": 45,
        "text": "41DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nNetilmicin Injection\nBrand Name Lotifar Injection (Strength: 150mg/2ml, 100mg/2ml)\nReconstitution Not required\nFurther Dilution IVinfusion\nDilute single dose in50to200ml ofdiluent.\nDiluents\nNS,D5\nAdministration Slow IV bolus\nAdminister slowly over aperiod of3to5minutes.\nIVinfusion\nAdminister thediluted solution over 1.5to2hours.\nStorage &StabilityRT(<25°C)\nAfter dilution 7days*\n*when diluted with compatible diluent atconcentration of3m g/m l .\nRemarks Should not bephysically premixed with other drugs, but should\nadministered separately inaccordance with the recommended route\nofadministration and dosage schedule .\nReferences Product leaflet Lotifar Injection (Duopharma (M) Sdn Bhd, Malaysia) .\nRevised date :15.12.2004 .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 46,
        "text": "42DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nPentamidine Isethionate Injection\nBrand Name DBLTMPentamidine Isethionate ForInjection (Strength: 300mg)\nReconstitution Reconstitute 1vial(300mg) with 3to5mlWFI.\nFurther Dilution Dilute therequired dose in50–250ml ofdiluent.\nDiluents\nNS,D5\nAdministration IVinfusion\nAdminister over atleast 60minutes.\nStorage &StabilityRT(21±2°C) Fridge (2°C-8°C)\nAfter reconstitution 48hours 48hours\nAfter dilution 24hours* 24hours\n*W hen diluted to1mg/ml and 2.5mg/ml indiluent .\nRemarks ■Direct bolus IVinjection orrapid administration must notbeused .\n■Keep patient supine during administration tominimize hypotension .\nReferences 1.Product leaflet DBLTMPentamidine Isethionate For Injection\n(Hospira Australia PtyLtd, Australia) .Revised date :1.12.2012.\n2.Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drug s\nGuide .Pharmaceutical Press .\n3.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 47,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\n43Piperacillin & Tazobactam Injection\nBrand Name\nReconstitution Reconstitute 1vial(4.5g)with 20mlofdiluent .\nDiluents\nWFI, NS,D5\nFurther Dilution IVinfusion\nDilute reconstituted solution with 50–150ml ofdiluent.\nDiluents\nNS,D5\nAdministration Slow IV bolus\nAdminister over 3–5minutes.\nIVinfusion\nAdminister over 20–30minutes.\nStorage &StabilityRT(25°C) Fridge (2°C-8°C)\nAfter reconstitution 24hours 7days\nRemarks ■This product donot contain preservative, therefore appropriate\naseptic technique should beperformed during preparation .\n■Whenever this product isused concurrently with another antibiotic,\nthedrug must beadministered separately .\n■This product should not beused with solution containing only\nsodium bicarbonate and should notbeadded toblood products or\nalbumin hydrolysates .\nReferences 1.Product leaflet Tapicin Powder For Injection (Yung Shin\nPharmaceutical Ind.Co,Ltd, Taiwan, ROC) .\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility.Contains: Piperacillin 4 g and Tazobactam 0.5 gTapicin Powder ForInjection (Strength :4.5g)"
    },
    {
        "page_number": 48,
        "text": "44DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nSulphamethoxazole -Trimethoprim Injection\nBrand Name DBLTMSulfamethoxazole 400mgand Trimethoprim 80mgConcentrate\nInjection BP(5mlperampoule)\nReconstitution Not required\nFurther Dilution Dilution Options:\n1.Dilute 1ampoule (5ml) to125mlofdiluent .\n2.Dilute 2ampoules (10ml)to250 mlofdiluent .\n3.Dilute 3ampoules (15ml)to500 mlofdiluent .\nDiluents\nD5, NS,D10\nAdministration IVinfusion\n■Administer slowly over 60–90minutes.\n■Duration ofinfusion should notexceed 1.5hours.\nStorage &StabilityRT\nAfter dilution 24hours\n*Donotrefrigerate theprepared solution.\nRemarks ■Must bediluted prior toadministration .\n■Must beadministered intravenously only intheform ofaninfusion\nsolution, and may notbeinjected undiluted either intravenously or\ndirect into infusion tube .\n■The prepared infusion should beshaken well toensure thorough\nmixing .Should visible turbidity orcrystallisation appear inthe\nsolution during itspreparation orinfusion, itmust bediscarded and\nreplaced byafreshly prepared solution .\nReferences 1.Product leaflet DBLTMSulfamethoxazole 400mgand Trimethoprim\n80mg Concentrate Injection BP(hameln pharmaceuticals GmbH,\nGermany) .Revised date :1.12.2012.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 49,
        "text": "DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\n45Vancomycin Injection\nBrand Name Celovan Powder For Solution For Injection/Infusion (Strength: 500mg)\nReconstitution Dissolve 500mg in10mlofWFI toobtain final concentration 50mg/ml.\nFurther Dilution Intermittent IVinfusion\n■Dilute reconstituted solutions with atleast 100mlofdiluent .\n■Max concentration= 5mg/ml .\n■Forfluid restricted patients, aconcentration ofupto10m g/m l may\nbeused .\nDiluents\nNS,D5\nAdministration Intermittent IVinfusion\n■Administered thedesired dose over aperiod ofatleast 60minutes.\n■Max rate = 10mg/minute.\n■1gdose isusually given over 2hours.\nStorage &StabilityRT(<25°C) Fridge (2°C-8°C)\nAfter dilution 48hours 48hours\nRemarks ■Not forIMadministration .\n■Watch for“red -man” syndrome, anonallergic histamine reaction\ncaused by rapid IVinfusion .Signs and symptoms include\nhypotension, pruritus, and maculopapular rash onface, neck, trunk\nand limbs .\nReferences 1.Product leaflet Celovan Vancomyci nPowder For Solution For\nInjection/Infusion (Mylan Laboratories Limited, India) .Revised\ndate :January 2018 .\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n3.Gray, A.,Wright, J.,Goodey ,V.and Bruce, L.,2011.Injectable Drugs\nGuide, Pharmaceutical Press, 2011.\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 50,
        "text": "46DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nVoriconazole Injection\nVfend® (Strength: 200mg)\nReconstitute 1vial(200mg) with 19mlofWFI (Concentration :10mg/m l\nandextractable volume :20ml).\nFurther dilute therequired volume ofreconstituted solution according\ntopatient’s BW toafinal concentration of0.5–5mg/ml.\nBody  \nWeight  \n(kg)Volume ofVFEND®Concentrate (10mg/ml ) required for:\n3mg/kg  \ndose (no. \nofvials)4mg/kg\ndose (no.\nofvials)6mg/kg  \ndose (no. \nofvials)8mg/kg  \ndose (no. \nofvials)9mg/kg dose  \n(no. ofvials)\n10 - 4m l (1) - 8ml (1) 9ml (1)\n15 - 6ml (1) - 12ml (1) 13.5ml(1)\n20 - 8ml (1) - 16ml (1) 18ml (1)\n25 - 10ml (1) - 20ml (1) 22.5ml(2)\n30 9ml (1) 12ml (1) 18ml (1) 24ml (2) 27ml (2)\n35 10.5ml(1) 14ml (1) 21ml (2) 28ml (2) 31.5ml(2)\n40 12ml (1) 16ml (1) 24ml (2) 32ml (2) 36ml (2)\n45 13.5ml(1) 18ml (1) 27ml (2) 36ml (2) 40.5ml(3)\n50 15ml (1) 20ml (1) 30ml (2) 40m l (2) 45ml (3)\n55 16.5ml(1) 22ml (2) 33ml (2) 44m l (3) 49.5ml(3)\n60 18ml (1) 24ml (2) 36ml (2) 48ml (3) 54ml (3)\n65 19.5ml(1) 26ml (2) 39ml (2) 52ml (3) 58.5ml(3)\n70 21ml (2) 28ml (2) 42ml (3) - -\n75 22.5ml(2) 30ml (2) 45ml (3) - -\n80 24ml (2) 32ml (2) 48ml (3) - -\n85 25.5ml(2) 34ml (2) 51ml (3) - -\n90 27ml (2) 36ml (2) 54ml (3) - -\n95 28.5ml(2) 38ml (2) 57ml (3) - -\n100 30ml (2) 40m l (2) 60ml (3) - -\nDiluents\nNS, HSD5, D5Brand Name\nReconstitution\nFurther Dilution\nAdministration IV infusion ONLY\n■Administer over 1 –2hours.\n■Maximum rate: 3mg/kg/hour."
    },
    {
        "page_number": 51,
        "text": "47DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nStorage &S tabilityFridge (2°C-8°C)\nAfter reconstitution 24hours\n*The product must beused immediately.\nRemarks ■Voriconazole must not beinfused concomitantly with any blood\nproduct orany short -term infusion ofconcentrated electrolytes,\neven ifthetwo infusions arerunning inseparate intravenous line.\n■Not recommended forIVbolus administration .\n■Must notbediluted with 4.2%sodium bicarbonate infusion .\nReferences Product leaflet Vfend®(Pharmacia &Upjohn Company, USA) .Revised\ndate :April 2014 .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 52,
        "text": "48DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nZidovudine Injection\nBrand Name Retrovir TM (Strength: 200mg/20ml)\nReconstitution Not required\nFurther Dilution ■Add and mix the required dose with diluent toobtain afinal\nconcentration ofeither 2m g/m l or4mg/ml .\n■Dilution must becarried outunder fullaseptic conditions .\nDiluent\nD5\nAdministration IVinfusion\n■Administer slowly over 1hour .\n■Avoid rapid infusion orbolus injection .\nStorage &StabilityRT(25°C) Fridge (5°C)\nAfter dilution 48hours 48hours\n*Any unused portion ofthevialshould bediscarded.\nRemarks ■Donotadminister asIMinjection .\n■Must beDILUTED prior toadministration .\n■Discard ifany visible turbidity appears intheproduct either before\norafter dilution orduring infusion .\nReferences 1.Product leaflet Retrovir ™(Glaxo Wellcome Operations, UK).Revised\ndate :11.4.2012.\n2.Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw Hill\nProfessional .\n*The information provided inthisguideline may beused asgeneral reference only. Please refer to  \nthecurrent product inserts forrelevant brand used infacility."
    },
    {
        "page_number": 53,
        "text": "49Appendix 1Glossary\nAppendix 2Best practices forinjection\nAppendix 3Storage conditions\nAppendix 4Conversions &calculationsAPPENDICES"
    },
    {
        "page_number": 54,
        "text": "50DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAPPENDIX 1:GLOSSARY\nNo. Name Definition\n1. Injection Use ofasyringe and needle topush fluids or\ndrugs into thebody ;often called a“shot .”\n2. Intravenous (IV) Into orwithin avein.Intravenous usually refers toa\nway ofgiving adrug orother substance through\naneedle ortube inserted intoavein.\n3. Intravenous (IV)bolus ■Amethod ofadministering concentrated\nmedication (diluted orundiluted) directly into\nthevein using asyringe through aneedleless\nport onanexisting IVline orasaline lock.\n■Adiscrete dose ofmedication orsolution given\nslowly over atleast 1minute .\n■Itisusually administered inasmall volume of\nfluid /medicine (max 20ml) that ispushed\nmanually into the vein slowly over atleast\n1minute .\n4. Intravenous (IV)push Intravenous push iscommonly used when rapid\nadministration ofamedication isneeded such as\ninemergency (less than 30seconds) .\n5. Continuous intravenous (IV)\ninfusionThe administration ofafluid into ablood vessel,\nusually over aprolonged period oftime .\n6. Intermittent intravenous (IV)\ninfusion■This isthe technique used toadminister an\ninjectable drug inanintravenous infusion over\naperiod oftime ranging from 20minutes to\nseveral hours .Repeated doses orsingle doses\naregiven inthisway.\n■The infusion may beconnected totheprimary\nintravenous giving set ortoasecondary\nadministration setviaaY-connector .\n■The volume ofintravenous fluid used todilute\nthe drug ranges from 50ml (the smallest\nintravenous fluid bag) upto500ml.Inclinical\npractice most drugs aregiven in100mland\naresettoinfuse over 20-30minutes .\n7. Intramuscular (IM) injection ■Intramuscular injections areadministered into\nthe muscle beneath thesubcutaneous tissue .\n■They aremost commonly given into thethigh\nor the gluteal muscle, and occasionally into\nthedeltoid muscle (which attaches the upper\narm totheshoulder) .\n■The volume given atany one site isusually\nlimited to5mlforthe thigh (or4mlifitisa\ndepot injection because depots can bemore\nirritant), and 2mlforthedeltoid muscle ."
    },
    {
        "page_number": 55,
        "text": "51DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nNo. Name Definition\n8. Subcutaneous (SC) injection ■Subcutaneous injections aregiven byinjecting\nafluid orasolid pellet into the subcutis (the\nfatty layer oftissue just under theskin) .\n■Appropriate sites for subcutaneous injection\ninclude :\n•The outer aspect oftheupper arm\n•The anterior aspect oftheupper arm\n•The abdomen below the costal margins to\ntheiliac crests\n•The anterior aspect ofthethigh\n9. Reconstitute The act ofadding diluent topowder tocreate a\nsolution .\n10. Dilution Toadd adiluent (e.g.,normal saline, sterile water)\ntoasolution ofmedication inorder tomake itless\nconcentrated ortoprovide additional solution for\nease ofadministration and titration ortodecrease\ntissue irritation .\nReferences:\n1.Ministry ofHealth, Malaysia, 2017. Safe Operating Procedure forAdministration ofIntravenous  \n(Bolus), Nursing Division.\n2.Gray, A.,W right, J.,Goodey, V.and Bruce, L.,2011. Injectable Drugs Guide. Pharmaceutical Press.\n3.https://www.cancer.gov/publications/dictionaries/cancer -terms/search [online]"
    },
    {
        "page_number": 56,
        "text": "52DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAPPENDIX 2: BEST PRACTICES FOR INJECTION\nGeneral Information :\n■Allpreparations should bedone using aseptic technique .\n■DoNOT usetheinitial concentrate ortheinfusion solution ifthere isany sign ofprecipitation\nand presence offoreign matter ineither one.\n■DoNOT mix other drugs totheinfusion solution toavoid anypossible drug interactions .\n■Any unused portion should bediscarded after therecommended period ofuse.\n■Formultiple usevials, reconstituted solution must belabelled with time and date immediately\nafter preparation and must beplaced under recommended storage condition .\n■Flush IVline before and after administration .The most com m on fluid administered asanIV\nflush issodium chloride 0.9%.Insome instances, glucose 5%may beused ifitismore suitable\nforusedue tocompatibility with theIVmedicine being administered .\n*This general information may not beapplicable toallthemedications stated inthis guideline .\nPlease refer totheproduct inserts orconsult your pharmacist forfurther information .\nTable 1:Infection prevention and control practices\nDo DoNot\nDO carry out hand hygiene (use soap and\nwater oralcohol rub), and wash carefully,\nincluding wrists and spaces between the\nfingers, foratleast 30seconds .\n(followWHO’s‘My 5moments for hand\nhygiene ')DONOT forget toclean your hands .\nDO use one pair ofnon-sterile gloves per\nprocedure orpatient .■DONOT usethesame pair ofgloves for\nmore than one patient .\n■DONOT wash gloves forreuse .\nDodisinfect theskin atthevenepuncture site. DO NOT touch the puncture site after\ndisinfecting it.\nDOdiscard theused device (aneedle and\nsyringe isasingle unit) immediately into a\nrobust sharps container .DONOT leave anunprotected needle lying\noutside thesharps container .\nDO seal thesharps container with a\ntamper -proof lid.DONOT overfill ordecant asharps container .\nDO immediately report any incident or\naccident linked toaneedle orsharp injury,\nand seek assistance ;start Post -Exposure\nProphylaxis (PEP) assoon aspossible,\nfollowing protocols .DO NOT delay PEP after exposure to\npotentially contaminated material ;beyond\n72hours, PEP isNOT effective .\nReferences:\n1.World Health Organization, 2010. W HO best practices for injections and related procedures  \ntoolkit (No. WHO/EHT/10.02). World Health Organization.\n2.Pharmaceutical Services Division, Penang State Health Department, 2016. Antimicrobial  \nDilution Protocol."
    },
    {
        "page_number": 57,
        "text": "53DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAPPENDIX 3: STORAGE CONDITIONS\nThestorage conditions formaterials and/or products and/or cosmetics should follow therequired\nstorage specification ofthematerials and/or products and/or cosmetics.\nWhere temperature isnotstated (interms ofrange) onthelabels ofthematerials and/or products\nand/or cosmetics thefollowing definitions should befollowed:\nON THELABEL MEANS\nFreezer The temperature isthermostatically controlled between\n-20°Cand -10°C\nRefrigerator The temperature isthermostatically controlled between 2°C\nand 8°C\nCold place The temperature does notexceed 8°C\nCool place The temperature isbetween 8°Cand 15°C\nRoom temperature The temperature isbetween 15°Cand 30°C\nW arm The temperature isbetween 30°Cand 40°C\nExcessive heat The temperature isabove 40°C\nDonotstore over 30°C The temperature isbetween 2°Cand 30°C\nDonotstore over 25°C The temperature isbetween 2°Cand 25°C\nDonotstore over 15°C The temperature isbetween 2°Cand 15°C\nDonotstore over 8°C The temperature isbetween 2°Cand 8°C\nDonotstore below 8°C The temperature isbetween 8°Cand 25°C\nDryplace Nomore than 75±5%relative humidity innormal storage\nconditions ;tobe provided tothe user inamoisture\nresistant container .\nProtect from light Tobeprovided totheuser inalight resistant container .\nReference:\nMinistry ofHealth Malaysia, 2nd Edition 2013. Guidelines onGood Distribution Practice (GDP)."
    },
    {
        "page_number": 58,
        "text": "54DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nAPPENDIX 4: CONVERSIONS &CALCULATIONS\nAccurate conversions and calculations of medication dosages are crucial to ensure safe drug  \nadministration.\n1. Metric measures\n1milligram (mg) =1,000 micrograms (mcg)\n1 gram (g) = 1,000 mg\n1kilogram (kg) = 1,000 g\n1 liter (L) = 1,000 milliliter (ml)\n2. Calculating dosages & administration rates\nConcentration ofsolution inm g/m l =mgof drug\nm l ofsolution\nInfusion rate inmg/minute =mgofdrugx flow rate (ml/hour) ÷60minutes\nm l ofsolution\nConcentration of solution in mcg/ml =m g  ofdrug x 1,000\nm l ofsolution\nInfusion rate inmcg/minute = mgofdrug x1,000x flow rate (ml/hour) ÷60minutes\nm l ofsolution\nInfusion rate in\nmcg/kg/minute =  m g  of drug x1,000x flow rate (ml/hour) ÷60 minutes ÷weight inkg\nm l ofsolution\nInfusion rate in ml/hour = m l of solution÷60 minutes\nInfusion rate in gtt/minute =   mlofsolutionx drip factor (gtt/ml)\ntime inminutes\nReference:\nSchull, P.D., 2009. McGraw -Hill’s IVDrug Handbook. McGraw HillProfessional."
    },
    {
        "page_number": 59,
        "text": "55DILUTION GU ID E LIN E  FOR  IN JE C T ABLE DRUGS\nREFERENCES\n[1] Clinical Pharmacy Unit, Pharmacy Department, Hospital Taiping .Hospital Taiping\nAntibiotics Dilution &Administration Protocol .(1sted.).Ministry OfHealth Malaysia .\n[2] Dilution Protocol 2017 Hospital Tuanku Ampuan Najihah, Kuala Pilah .Ministry Of\nHealth Malaysia .\n[3] Gray, A.,Wright, J.,Goodey, V.and Bruce, L.,2011.Injectable Drugs Guide .\nPharmaceutical Press .\n[4] Mimsgateway .com .2020 .Mims Gateway >Malaysia >Overview .[online] Available at:\n<http ://www .mimsgateway .com/malaysia/overview> .\n[5] Ministry ofHealth Malaysia, 2ndEdition 2013 .Guidelines onGood Distribution\nPractice (GDP) .\n[6] Ministry ofHealth, Malaysia, 2017.Safe Operating Procedure forAdministration of\nIntravenous (Bolus), Nursing Division .\n[7] Ojerinde, A.and Adejumo, P.,2014 .Factors Associated W ith Medication Errors\nAmong Health Workers InUniversity College Hospital, Nigeria .IOSR Journal of\nNursing and Health Science, 3(3),pp.22-33.\n[8] Pharmaceutical Services Division, Penang State Health Department, 2016 .\nAntimicrobial Dilution Protocol .\n[9] Pharmacy .gov.my.2020 .Formulari Ubat KKM (FUKKM) |Pharmaceutical Services\nProgramme .[online] Available at:<https ://www .pharmacy .gov.my/v 2/en/apps/fukkm> .\n[10] Schull, P.D.,2009 .McGraw -Hill’s IVDrug Handbook .McGraw HillProfessional .\n[11] Selangor State Health Department (2017 ).Dilution Protocol .(1sted.).Ministry Of\nHealth Malaysia .\n[12] World Health Organization, 2010 .W HO best practices forinjections and related\nprocedures toolkit (No.WHO/EHT/ 10.02).World Health Organization ."
    },
    {
        "page_number": 60,
        "text": "NOTE:"
    },
    {
        "page_number": 62,
        "text": "Pharmaceutical Services Programme  \nMinistry of Health Malaysia\nLot 36, Jalan Universiti  \n46200 Petaling Jaya  \nSelangor Darul Ehsan  \nTel :03-78413200\nFax :03-79682222\nwww.pharmacy.gov.my"
    }
]